Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Plan B lifts women's health for Teva: Second-quarter sales of the emergency contraceptive help drive a 3.9 percent increase in Teva Pharmaceuticals' women's health business to $80 million. Teva is in the midst of de-stocking Plan B inventory as Plan B One-Step -- a single-pill version of the two-pill original product -- becomes available in August, the Jerusalem-based firm said July 28 (1"The Tan Sheet" July 20, 2009). During a same-day earnings call, President and CEO Shlomo Yanai said the women's health business "has outstanding prospects for growth" and Teva intends to expand its oral contraceptive offerings

You may also be interested in...



Sales & Earnings In Brief

Launches underlie Reckitt consumer growth: Recent line extensions, including Nurofen Express pain reliever and Strepsils Cool throat lozenges, enable Reckitt Benckiser's Health & Personal Care business to grow 16 percent to $869.5 million (533 million U.K. pounds under Oct. 27 conversion rates) during the fiscal 2009 third quarter. "Those products are doing extremely well and clearly underpin the growth rate that we are seeing" in the segment, CEO Bart Becht said Oct. 27. In a same-day release, the U.K. firm cited Dettol hygiene products, Gaviscon antacid and Mucinex cough/cold remedy as major growth drivers. Becht told analysts to expect additional launches in February 2010. Reckitt reported overall net revenue of $3.1 billion in the July-September period, a 7 percent gain. Quarterly net income was $582.4 million, up 12 percent

Sales & Earnings In Brief

Launches underlie Reckitt consumer growth: Recent line extensions, including Nurofen Express pain reliever and Strepsils Cool throat lozenges, enable Reckitt Benckiser's Health & Personal Care business to grow 16 percent to $869.5 million (533 million U.K. pounds under Oct. 27 conversion rates) during the fiscal 2009 third quarter. "Those products are doing extremely well and clearly underpin the growth rate that we are seeing" in the segment, CEO Bart Becht said Oct. 27. In a same-day release, the U.K. firm cited Dettol hygiene products, Gaviscon antacid and Mucinex cough/cold remedy as major growth drivers. Becht told analysts to expect additional launches in February 2010. Reckitt reported overall net revenue of $3.1 billion in the July-September period, a 7 percent gain. Quarterly net income was $582.4 million, up 12 percent

With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics

Teva Pharmaceutical Industries likely will gain another three years of exclusivity in the branded nonprescription emergency contraceptive market with FDA's approval of a revised dosage of Plan B

Related Content

Topics

UsernamePublicRestriction

Register

PS103191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel